What Are GLP-1 Receptor Agonists?

Glucagon-like peptide-1 (GLP-1) is a hormone the gut releases after eating. It signals the pancreas to release insulin, slows gastric emptying, and acts on brain regions involved in appetite. GLP-1 receptor agonists are synthetic compounds designed to mimic or extend these effects by binding to the same receptor.

Several GLP-1 receptor agonists have received FDA approval as branded prescription drugs. Semaglutide is approved under the brand names Ozempic and Wegovy for specific indications. Tirzepatide, which also targets the GIP receptor, is approved as Mounjaro and Zepbound. Liraglutide is approved as Victoza and Saxenda. Research-chemical versions of these or related peptides sold outside the prescription system are not FDA approved and are not equivalent to those branded drugs.

Because approved GLP-1 drugs have undergone large, multi-year clinical trials, the adverse-effect data for this class is unusually detailed compared to most peptide categories. The findings below draw from that published trial record.

What GI Side Effects Does the Research Document?

Gastrointestinal adverse events are the most consistently reported finding across GLP-1 trials. In the SUSTAIN 6 cardiovascular outcomes trial of semaglutide (published in the New England Journal of Medicine in 2016, n=3,297), nausea occurred in 20.3% of the semaglutide group versus 5.0% in the placebo group. Vomiting and diarrhea followed similar patterns, with vomiting at 9.2% versus 2.3% for placebo.

The SCALE Obesity and Prediabetes trial of liraglutide 3.0 mg (New England Journal of Medicine, 2015, n=3,731) found that 63.5% of participants in the liraglutide group reported nausea at some point during the 56-week study, compared with 27.1% in the placebo group. Most nausea was rated mild to moderate in severity and was most frequent during the first weeks of the trial.

Constipation appears more prominently with semaglutide than with liraglutide in head-to-head comparisons. The STEP 1 trial of subcutaneous semaglutide 2.4 mg (New England Journal of Medicine, 2021, n=1,961) reported constipation in 24.2% of the semaglutide group versus 11.1% for placebo. Gastroesophageal reflux disease was also elevated at 8.3% versus 2.0%. These GI effects are thought to relate to slowed gastric motility, a direct pharmacological action of GLP-1 receptor activation.

Are There Serious or Rare Adverse Signals?

Pancreatitis has been a closely watched signal since early GLP-1 development. The LEADER trial of liraglutide (New England Journal of Medicine, 2016, n=9,340) reported acute pancreatitis in 18 participants in the liraglutide group and 23 in the placebo group, a difference that was not statistically significant. Regulatory agencies have nonetheless required pancreatitis warnings on GLP-1 drug labels given the biological plausibility of the signal.

Heart rate elevation is another documented finding. In the STEP 1 trial, mean heart rate increased by approximately 1 to 2 beats per minute more in the semaglutide group than in the placebo group. The LEADER trial found a mean increase of about 3 beats per minute with liraglutide. The long-term clinical significance of this modest elevation remains an active area of research.

Thyroid C-cell tumors appeared in rodent studies of liraglutide and semaglutide at doses producing sustained GLP-1 receptor stimulation. Regulatory agencies note that the relevance of this finding to humans is uncertain because human thyroid tissue expresses GLP-1 receptors at much lower density than rodent tissue. These drugs carry a boxed warning for this signal in their FDA-approved labeling, and people with a personal or family history of medullary thyroid carcinoma were excluded from major trials. Gallbladder disease, including cholelithiasis, has also been reported at higher rates in GLP-1 trial participants than in placebo groups, a finding attributed partly to rapid weight loss affecting bile composition.

How Do Injection-Site and Systemic Effects Compare?

Subcutaneous injection-site reactions, including redness, bruising, and mild pain, are reported in GLP-1 trials but at relatively low rates. In the STEP 1 trial, injection-site reactions occurred in 0.9% of the semaglutide group and 0.3% of the placebo group. These rates are lower than those seen with some other injectable peptide classes, possibly because GLP-1 agonists are typically injected once weekly rather than daily.

Headache and fatigue appear in trial adverse-event tables more often than injection-site effects. In the SCALE trial of liraglutide, headache was reported in 13.6% of the active group versus 10.5% for placebo. These systemic effects are generally classified as mild and transient in the published literature.

Hypoglycemia risk depends heavily on co-administration with other agents. When GLP-1 receptor agonists are used as monotherapy in trials of people without diabetes, severe hypoglycemia is rare. The risk increases substantially when combined with sulfonylureas or insulin, a pattern documented across multiple trials and reflected in prescribing information for approved drugs.

What Does the Evidence Say About Long-Term Safety?

The SELECT trial of semaglutide 2.4 mg (New England Journal of Medicine, 2023, n=17,604) followed participants with overweight or obesity and established cardiovascular disease for a mean of 34 months. It found a 20% reduction in major adverse cardiovascular events in the semaglutide group, which was the primary endpoint. On the safety side, serious adverse events occurred in 33.4% of the semaglutide group versus 36.4% for placebo, suggesting no increase in overall serious event burden over that timeframe.

Longer-term data beyond three to four years remains limited for newer high-dose formulations. Post-marketing surveillance programs and ongoing registry studies are collecting data on outcomes including thyroid cancer incidence, long-term cardiovascular effects, and effects on bone density, none of which are fully characterized in the existing trial record.

It's worth noting that the trial populations for approved GLP-1 drugs are specific: participants typically meet defined criteria for type 2 diabetes, obesity, or cardiovascular risk. Extrapolating the safety profile to other populations, including healthy individuals or those using unregulated research-chemical versions, is not supported by the published data. Anyone considering a GLP-1 compound for any purpose should discuss the full risk picture with a licensed healthcare provider who can review their individual medical history.

Frequently asked questions

Does nausea from GLP-1 compounds go away over time?

Trial data suggests it often does. In the STEP 1 trial of semaglutide, nausea rates peaked during the dose-escalation period in the first 20 weeks and declined substantially by week 60, even though participants remained on the drug. The SCALE trial of liraglutide showed a similar pattern, with nausea most common in the first four weeks. Whether this reflects physiological adaptation or participant dropout is debated in the literature, but the trend toward improvement over time appears consistently across studies.

Is the pancreatitis risk from GLP-1 drugs considered confirmed?

No, the causal link is not confirmed. Large cardiovascular outcomes trials, including LEADER and SUSTAIN 6, did not find statistically significant differences in pancreatitis rates between active and placebo groups. However, because the biological mechanism is plausible and some smaller observational studies have suggested an association, regulatory agencies have required pancreatitis warnings on approved GLP-1 drug labels. The FDA and European Medicines Agency have both reviewed this signal and concluded that the evidence is insufficient to establish causation, while still recommending caution in people with a history of pancreatitis.

Do research-chemical GLP-1 peptides have the same side-effect profile as approved drugs?

That question cannot be answered from the published literature, because research-chemical versions have not undergone the large controlled trials that generated the safety data described in this article. The adverse-effect profiles documented in STEP, LEADER, SUSTAIN, and SELECT trials apply specifically to the pharmaceutical-grade, FDA-approved formulations used in those studies. Research chemicals are not subject to the same manufacturing standards, purity testing, or regulatory oversight, so their actual safety profile in humans is unknown. They are not FDA approved.

Sources

  1. Wilding et al., 2021, New England Journal of Medicine (STEP 1 trial, semaglutide 2.4 mg) Primary source for GI and injection-site adverse events
  2. Pi-Sunyer et al., 2015, New England Journal of Medicine (SCALE trial, liraglutide 3.0 mg) Nausea and systemic adverse-event rates
  3. Marso et al., 2016, New England Journal of Medicine (LEADER trial, liraglutide) Pancreatitis signal and heart rate data
  4. Lincoff et al., 2023, New England Journal of Medicine (SELECT trial, semaglutide 2.4 mg) Long-term serious adverse event rates
  5. Marso et al., 2016, New England Journal of Medicine (SUSTAIN 6 trial, semaglutide) Nausea and vomiting rates versus placebo

Educational and informational content only. This is not medical advice, diagnosis, or treatment. The compounds discussed are research compounds that are not approved for human use outside specific prescribed contexts. Always consult a qualified, licensed clinician before making any health decision.